

Muscarinic Acetylcholine Receptor M2 - Pipeline Review, H1 2020

https://marketpublishers.com/r/MD240AEFD6C9EN.html

Date: March 2020

Pages: 74

Price: US\$ 3,500.00 (Single User License)

ID: MD240AEFD6C9EN

Abstracts

Muscarinic Acetylcholine Receptor M2 - Pipeline Review, H1 2020

SUMMARY

According to the recently published report 'Muscarinic Acetylcholine Receptor M2 - Pipeline Review, H1 2020'; Muscarinic Acetylcholine Receptor M2 (CHRM2) pipeline Target constitutes close to 7 molecules.

Muscarinic Acetylcholine Receptor M2 (CHRM2) - Muscarinic cholinergic receptor 2 is an acetylcholine receptor. It is expressed in various regions of the brain including the cerebellum, cerebral cortex, hippocampus, medulla, striatum, and thalamus, and in lung and prostate. It mediates smooth muscle contractility. Increase in M2 receptor has been associated with depression.

The report 'Muscarinic Acetylcholine Receptor M2 - Pipeline Review, H1 2020' outlays comprehensive information on the Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 1, 4 and 1 respectively. Report covers products from therapy areas Central Nervous System, Genito Urinary System And Sex Hormones, Cardiovascular, Dermatology, Genetic Disorders and Respiratory which



include indications Alzheimer's Disease, Depression, Overactive Bladder, Parkinson's Disease, Amnesia, Amyotrophic Lateral Sclerosis, Angelman Syndrome, Anxiety Disorders, Axillary Hyperhidrosis, Fragile X Syndrome, Infantile Spasm (West Syndrome), Movement Disorders, Multiple Sclerosis, Obstructive Sleep Apnea, Pain, Psychosis, Rett Syndrome, Schizophrenia, Stroke, Tuberous Sclerosis and Urinary Incontinence.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Muscarinic Acetylcholine Receptor M2 (CHRM2)

The report reviews Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics and enlists all their major and minor projects

The report assesses Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics



REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Muscarinic Acetylcholine Receptor M2 (CHRM2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Muscarinic Acetylcholine Receptor M2 (CHRM2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Contents

Introduction

Global Markets Direct Report Coverage

Muscarinic Acetylcholine Receptor M2 (CHRM2) - Overview

Muscarinic Acetylcholine Receptor M2 (CHRM2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Muscarinic Acetylcholine Receptor M2 (CHRM2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Muscarinic Acetylcholine Receptor M2 (CHRM2) - Companies Involved in Therapeutics

Development

Anavex Life Sciences Corp

Apnimed Inc

Dermavant Sciences Inc

FemmePharma Global Healthcare Inc

Karuna Therapeutics Inc

TheraVida Inc

Muscarinic Acetylcholine Receptor M2 (CHRM2) - Drug Profiles

(atomoxetine + oxybutynin) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(oxybutynin + pilocarpine) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(pilocarpine + tolterodine) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(trospium chloride + xanomeline) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress



ANAVEX-141 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

blarcamesine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

oxybutynin chloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

oxybutynin chloride ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Muscarinic Acetylcholine Receptor M2 (CHRM2) - Dormant Products

Muscarinic Acetylcholine Receptor M2 (CHRM2) - Discontinued Products

Muscarinic Acetylcholine Receptor M2 (CHRM2) - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer



List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Indications, H1 2020

Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Pipeline by Anavex Life Sciences Corp, H1 2020

Pipeline by Apnimed Inc, H1 2020

Pipeline by Dermavant Sciences Inc, H1 2020

Pipeline by FemmePharma Global Healthcare Inc, H1 2020

Pipeline by Karuna Therapeutics Inc, H1 2020

Pipeline by TheraVida Inc, H1 2020

Dormant Products, H1 2020

Dormant Products, H1 2020 (Contd..1), H1 2020

Discontinued Products, H1 2020



List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Mechanism of Actions, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

COMPANIES MENTIONED

Anavex Life Sciences Corp
Apnimed Inc
Dermavant Sciences Inc
FemmePharma Global Healthcare Inc
Karuna Therapeutics Inc
TheraVida Inc



I would like to order

Product name: Muscarinic Acetylcholine Receptor M2 - Pipeline Review, H1 2020

Product link: https://marketpublishers.com/r/MD240AEFD6C9EN.html

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/MD240AEFD6C9EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970